DK0459819T3 - Farmakologisk aktiv CNS-forbindelse - Google Patents

Farmakologisk aktiv CNS-forbindelse

Info

Publication number
DK0459819T3
DK0459819T3 DK91304935.9T DK91304935T DK0459819T3 DK 0459819 T3 DK0459819 T3 DK 0459819T3 DK 91304935 T DK91304935 T DK 91304935T DK 0459819 T3 DK0459819 T3 DK 0459819T3
Authority
DK
Denmark
Prior art keywords
hydrogen
halo
alkyl
pharmacologically active
nitro
Prior art date
Application number
DK91304935.9T
Other languages
English (en)
Inventor
Michael John Leach
Malcolm Stuart Nobbs
Ramachandran Iyer
Clive Leonard Yeates
Philip Alan Skone
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of DK0459819T3 publication Critical patent/DK0459819T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DK91304935.9T 1990-06-01 1991-05-31 Farmakologisk aktiv CNS-forbindelse DK0459819T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012316A GB9012316D0 (en) 1990-06-01 1990-06-01 Pharmacologically active cns compounds

Publications (1)

Publication Number Publication Date
DK0459819T3 true DK0459819T3 (da) 1996-09-02

Family

ID=10676964

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91304935.9T DK0459819T3 (da) 1990-06-01 1991-05-31 Farmakologisk aktiv CNS-forbindelse

Country Status (25)

Country Link
EP (2) EP0679645A1 (da)
JP (1) JPH06340634A (da)
KR (1) KR920000733A (da)
AT (1) ATE141263T1 (da)
AU (2) AU652753B2 (da)
CA (1) CA2043640A1 (da)
CZ (1) CZ281070B6 (da)
DE (1) DE69121317T2 (da)
DK (1) DK0459819T3 (da)
ES (1) ES2093078T3 (da)
FI (1) FI912623A (da)
GB (1) GB9012316D0 (da)
GR (1) GR3021237T3 (da)
HU (2) HUT58707A (da)
IE (1) IE911861A1 (da)
IL (2) IL113599A (da)
MY (2) MY136248A (da)
NO (1) NO180375C (da)
NZ (3) NZ248501A (da)
PL (2) PL166656B1 (da)
PT (1) PT97827B (da)
RU (1) RU2091374C1 (da)
SK (1) SK278444B6 (da)
TW (1) TW224460B (da)
ZA (1) ZA914165B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
ATE133068T1 (de) * 1991-01-30 1996-02-15 Wellcome Found Wasserlösliche tabletten
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
WO1994014780A1 (en) * 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9319341D0 (en) * 1993-09-17 1993-11-03 Wellcome Found Novel process
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6440965B1 (en) * 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
BRPI0014526C1 (pt) 1999-09-16 2021-05-25 Mitsubishi Tanabe Pharma Corp compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
MXPA02010693A (es) 2000-04-28 2003-03-10 Tanabe Seiyaku Co Compuestos ciclicos.
US7205297B2 (en) 2000-07-24 2007-04-17 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
NZ527741A (en) 2001-02-26 2005-02-25 Tanabe Seiyaku Co Pyridopyrimidine or naphthyridine derivative
IL162859A0 (en) * 2002-02-05 2005-11-20 Novo Nordisk As Novel aryl-and heteroarylpiperazines
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
AU2006264966B2 (en) 2005-07-04 2013-02-21 High Point Pharmaceuticals, Llc Histamine H3 receptor antagonists
EP2038256A1 (en) 2006-05-23 2009-03-25 TransTech Pharma, Inc 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ']-bipyridine and its use as a medicament
CA2659570C (en) 2006-05-29 2015-10-06 High Point Pharmaceuticals, Llc 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
JP2014517016A (ja) 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
EA036446B1 (ru) 2016-06-14 2020-11-11 Новартис Аг Соединения и композиции для подавления активности shp2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE518622A (da) *
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds

Also Published As

Publication number Publication date
EP0679645A1 (en) 1995-11-02
PL170373B1 (pl) 1996-12-31
GB9012316D0 (en) 1990-07-18
CZ281070B6 (cs) 1996-06-12
NZ248501A (en) 1997-03-24
IL98330A (en) 1996-10-31
JPH06340634A (ja) 1994-12-13
KR920000733A (ko) 1992-01-29
AU680252B2 (en) 1997-07-24
ZA914165B (en) 1993-03-01
AU6745594A (en) 1994-09-15
IE911861A1 (en) 1991-12-04
CS164391A3 (en) 1992-02-19
FI912623A0 (fi) 1991-05-31
PT97827B (pt) 1998-10-30
ATE141263T1 (de) 1996-08-15
EP0459819A3 (en) 1992-03-11
PL166656B1 (pl) 1995-06-30
FI912623A (fi) 1991-12-02
NO912100L (no) 1991-12-02
AU7809791A (en) 1991-12-05
IL98330A0 (en) 1992-06-21
PT97827A (pt) 1992-03-31
EP0459819A2 (en) 1991-12-04
DE69121317T2 (de) 1997-01-02
HU911826D0 (en) 1991-12-30
NO180375C (no) 1997-04-09
TW224460B (da) 1994-06-01
ES2093078T3 (es) 1996-12-16
NZ272001A (en) 1997-03-24
HUT58707A (en) 1992-03-30
IL113599A0 (en) 1995-08-31
CA2043640A1 (en) 1991-12-02
HU211649A9 (en) 1995-12-28
IL113599A (en) 1997-09-30
MY109958A (en) 1997-10-31
EP0459819B1 (en) 1996-08-14
DE69121317D1 (de) 1996-09-19
NZ238360A (en) 1997-03-24
SK278444B6 (en) 1997-05-07
MY136248A (en) 2008-08-29
NO180375B (no) 1996-12-30
AU652753B2 (en) 1994-09-08
GR3021237T3 (en) 1997-01-31
RU2091374C1 (ru) 1997-09-27
NO912100D0 (no) 1991-05-31

Similar Documents

Publication Publication Date Title
DK0459819T3 (da) Farmakologisk aktiv CNS-forbindelse
FI89709B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara arylderivat
HUP9901113A1 (hu) Herbicid hatású és növényi növekedést szabályozó hatású 2-amino-4-biciklo-amino-1,3,5-triazinok
DK0655996T3 (da) Substituerede benzylamino-nitrogenholdige, ikke-aromatiske, heterocykliske forbindelser
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
BR8502972A (pt) Processo para a preparacao de 5-amino-4-heterociclil-1-fenilpirazois,composicoes herbicidas,aplicacao,processos para a preparacao de composicoes e para a preparacao de derivados de acrilonitrila
ID23954A (id) Tetrahidrogama-karbolin
DK291488D0 (da) Alkansulfonanilidderivater
ES8801639A1 (es) Procedimiento para la obtencion de derivados del acido barbiturico
ATE84028T1 (de) Biologisch aktive verbindungen.
ATE205209T1 (de) Chinolincarbonsäurederivate und ihre salze
BR9600979A (pt) Composto processo para combater fungos fitopatogênicos composição fungicida e processo de preparação de um composto
DK553482A (da) Fremgangsmaade til fremstilling af n,n-disubstituerede alkenamider og phenylalkenamider
DK0385721T3 (da) Fremgangsmåde til fremstilling af lactamderivater
TH11828EX (th) สารประกอบต่าง ๆ ที่เกี่ยวกับ cns ซึ่งออกฤทธิ์ทางเภสัชวิทยา
NO954109L (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte 5-arylpyrimidiner